EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ganglioside alterations in alzheimers disease and treatment of alzheimers disease with gm 1



Ganglioside alterations in alzheimers disease and treatment of alzheimers disease with gm 1



Neurobiology of Aging 11(1): 76




(PDF emailed within 1 workday: $29.90)

Accession: 031536984

Download citation: RISBibTeXText



Related references

Enhanced binding to NMDA receptors in the striatum of Parkinsons disease, Alzheimers disease and mixed Parkinsons disease/Alzheimers disease patients. Society for Neuroscience Abstracts 19(1-3): 194, 1993

CD40 ligand is localized in astrocytes and is increased in Alzheimers disease and in animal models of Alzheimers disease and brain injury. Society for Neuroscience Abstracts 27(2): 2563, 2001

Apolipoprotein E levels in plasma and CSF from members of the Swedish Alzheimers disease APP 670/671 Mutation family and sporadic Alzheimers disease cases. Neurobiology of Aging 17(4 SUPPL ): S59, 1996

Preventive or therapeutic agents for Alzheimers disease a screening method of Alzheimers disease and Tau-protein kinase I originated from human being. Official Gazette of the United States Patent & Trademark Office Patents 1216(3): 2995, Nov 17, 1998

PET amyloid imaging as a tool for early diagnosis and identifying patients Alzheimers disease at risk for progression to Alzheimers disease. Alzheimer's Research & Therapy 3(2), 2011

Methodology and initial mr evaluations in alzheimers disease a preliminary report from cerad consortium to establish a registry for alzheimers disease. Neurology 40(4 SUPPL 1): 227, 1990

SPECT in Alzheimers disease Perfusion patterns, demographics and correlations with the Alzheimers disease assessment scale-cognitive subscale. Neurology 52(6 SUPPL 2): A367-A368, April 12, 1999

Longitudinal assessment of probable alzheimers disease 2 year follow up data from the consortium to establish a registry for alzheimers disease cerad. Neurology 40(4 SUPPL 1): 450, 1990

Autoradiographic study of galanin binding in the normal and Alzheimers disease brain Evidence for increased receptor occupancy in Alzheimers disease. Society for Neuroscience Abstracts 22(1-3): 204, 1996

Detection and measurement of alzheimers disease associated protein adap in cerebrospinal fluid csf an antemortem marker for alzheimers disease. Society for Neuroscience Abstracts 17(1-2): 1259, 1991

Clinical features and predictors of progression in patients with Alzheimers disease and with the Lewy body variant of Alzheimers disease. Neurology 50(4 SUPPL 4): A182, April, 1998

Why home health services are provided to Alzheimers disease patients in Californias Alzheimers disease program: an exploration. Home health care services quarterly4(2-3): 111-125, 1993

Autoradiographic study of iodoclonidine binding in normal and Alzheimers disease brain Evidence for preservation of alpha-2 adrenergic receptors in Alzheimers disease. Society for Neuroscience Abstracts 23(1-2): 1896, 1997

Microglial responses in Alzheimers disease Recent studies in transgenic mice and Alzheimers disease brains. Wood, Paul L , Reprint Author Neuroinflammation: Mechanisms and management: 267-282, 2003

Assessing quality of life in Alzheimers disease Ratings by members of the Alzheimers Disease Cooperative Study. Neurology 50(4 SUPPL 4): A301, April, 1998